Follistatin-like 1 protects mesenchymal stem cells from hypoxic damage and enhances their therapeutic efficacy in a mouse myocardial infarction model

• Published in: Stem cell research & therapy Vol. 10; no. 1; p. 17
• Main Authors: Shen, Han, Cui, Guanghao, Li, Yanqiong, Ye, Wenxue, Sun, Yimin, Zhang, Zihan, Li, Jingjing, Xu, Guiying, Zeng, Xiansheng, Zhang, Yanxia, Zhang, Wencheng, Huang, Zan, Chen, Weiqian, Shen, Zhenya
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 11.01.2019; BioMed Central; BMC
• Subjects: Animals; Anoxemia; Apoptosis; Apoptosis - genetics; Bone marrow; Cardiac function; Cardiomyocytes; Care and treatment; Cell culture; Cell death; Cell growth; Cell Hypoxia - genetics; Cell Proliferation - genetics; Cell Survival; Coronary artery; Disease Models, Animal; EF hand proteins; Flow cytometry; Follistatin; Follistatin-like 1; Follistatin-Related Proteins - genetics; Genetically modified organisms; Heart; Heart attack; Heart attacks; Heart cells; Humans; Hypoxia; Inflammation; Ischemia; Lentivirus - genetics; Mesenchymal Stem Cell Transplantation; Mesenchymal stem cells; Mesenchymal Stem Cells - cytology; Mesenchymal Stem Cells - metabolism; Mesenchyme; Mice; Myocardial infarction; Myocardial Infarction - genetics; Myocardial Infarction - physiopathology; Myocardial Infarction - therapy; Myocardium - metabolism; Myocardium - pathology; Myocytes, Cardiac - metabolism; Myocytes, Cardiac - pathology; Neovascularization; Neovascularization, Physiologic - genetics; Novels; Retention; Stem cell transplantation; Stem cells; Surgery; Survival; Transplantation; Vascularization; Myocardial infarction; Transplantation; Follistatin-like 1; Survival; Mesenchymal stem cells

Cell therapy remains the most promising approach against ischemic heart injury. However, poor survival of engrafted cells in ischemic sites diminishes its therapeutic efficacy. Follistatin-like 1 (Fstl1) is documented as a novel pro-survival cardiokine for cardiomyocytes, and it is protective during...